sh-Oligopeptide-4 for Hair Regrowth

Evidence Review created on 11/09/2026 using AI4L + evidence-mcp / GPT 6

Also known as: Synthetic Human Oligopeptide-4, Recombinant Human Thymosin Beta-4, Thymosin β4, Tβ4

Motivation

sh-Oligopeptide-4 is a laboratory-produced peptide used in cosmetic formulations and discussed as a possible way to influence hair growth. It is linked to a naturally occurring human protein involved in how cells move and repair tissue. Interest in this ingredient sits at the intersection of scalp care, hair restoration, and the wish to maintain appearance and well-being with age.

The surrounding research takes several forms: experiments on hair follicles and animals, studies of related proteins on scalp conditions, and human studies of mixtures containing several growth-related ingredients. These approaches ask different questions. A result for a mixture, an injection, or a laboratory preparation may have a different meaning from a result for a single ingredient applied to intact skin.

This review examines the identity of sh-Oligopeptide-4, evidence relevant to hair regrowth, possible adverse effects, and the practical meaning of formulation and delivery. It also examines what is known about dosing, ongoing use, and measuring change, with a focus on adults weighing hair restoration within broader health and longevity goals.

Benefits - Risks - Protocol - Conclusion

These resources explain the peptide’s biological rationale and the limits of translating it into hair treatment.

No qualifying overview was verified from Patrick, Kresser, or Lifespan; incomplete site searches limit claims of absence.

Grokipedia

Thymosin beta-4

Background on the parent protein and its biological functions. It is not a dedicated evaluation of sh-Oligopeptide-4 formulations, and its summaries are not used as clinical evidence here.

Examine

No dedicated Examine article was found for sh-Oligopeptide-4 or thymosin beta-4.

ConsumerLab

No dedicated article was located. ConsumerLab’s search did not return usable ingredient-specific results, so absence could not be confirmed.

Systematic Reviews

These reviews cover peptide mixtures relevant to the ingredient, rather than isolated sh-Oligopeptide-4.

No systematic review specifically testing isolated sh-Oligopeptide-4 was located; long-term ingredient-specific safety is also unrepresented.

Mechanism of Action

The Korea Cosmetic Association, whose members sell cosmetics, defines sh-Oligopeptide-4 as a recombinant human peptide (made using engineered cells) based on the human gene for thymosin beta-4, produced by fermentation in Escherichia coli. Its listed function is skin conditioning, not demonstrated hair regrowth (Korea Cosmetic Association ingredient dictionary). Commercial identity therefore requires the actual sequence and formulation; full-length thymosin, modified delivery peptides, and multi-ingredient products are not automatically interchangeable.

Thymosin beta-4 binds actin (a protein forming the cell’s internal scaffolding). Rodent and follicle-cell experiments linked thymosin beta-4 to cell movement, differentiation, and hair growth (Philp 2004). This is not selective blockade of the hormonal process behind pattern hair loss. An opposing explanation is context-dependent suppression of hair production: an inventor-authored patent reports inhibition in cultured human follicles; its commercial interest and laboratory setting limit interpretation (Armbruster–Paus–Langan patent).

Delivery is a separate uncertainty: thymosin beta-4 has poor membrane permeability, prompting experimental carrier development (Fu 2019). Human scalp distribution, follicular concentration, local half-life, receptor selectivity, and metabolic-enzyme contributions have not been established for marketed sh-Oligopeptide-4. Protein breakdown is plausible, but no validated scalp metabolic pathway supports drug-interaction predictions. Intravenous recombinant thymosin beta-4 had a single-dose half-life of approximately 0.5–2.084 hours; this does not establish topical residence time (Wang 2021).

Historical Context & Evolution

Interest in thymosin beta-4 for hair grew from tissue-repair research, rather than from a clinical program proving reversal of human pattern hair loss. Experimental work examined hair-follicle cells, topical exposure in rodents, and genetically increased peptide expression. Mice engineered to overexpress thymosin beta-4 regrew hair faster, while knockout mice regrew it more slowly (Gao 2015). These models address biological plausibility; genetically altered animals do not establish the effect of applying a cosmetic serum.

Commercial development subsequently included QR678 and QR678 Neo, mixtures of growth factors or mimicking peptides rather than isolated sh-Oligopeptide-4. The developers disclosed patents for their formulations (Kapoor 2020). That ownership is relevant when weighing the associated clinical literature. Studies moved into human injections and, later, combined treatment around hair transplantation; the latter’s corrected report described better hair measurements with the mixture plus transplantation (Gold 2025).

A separate research direction tested recombinant thymosin beta-4 on inflammatory scalp disease, measuring flaking and skin-barrier outcomes rather than hair regrowth (Yu 2021). The evolution is therefore from laboratory rationale to formulation-specific human observations, with an unresolved connection between those observations and the individual cosmetic ingredient. Neither favorable mixture studies nor unfavorable laboratory findings alone settle its clinical value.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: replicated human trials isolating sh-Oligopeptide-4 were not found.

Medium 🟩 🟩

No benefit reaches Medium: available human studies test mixtures or a separately specified recombinant protein formulation, not verified equivalent sh-Oligopeptide-4 alone.

Low 🟩

Hair Regrowth ⚠️ Conflicted

A corrected mixture study reports hair improvement around transplantation (Gold 2025). The ingredient’s contribution is unisolated. Conversely, an inventor-authored patent reports thymosin beta-4 inhibited cultured human-follicle hair production (Armbruster–Paus–Langan patent). Different preparations and settings prevent reconciliation; the net evidence is indirect and uncertain.

Magnitude: Corrected final hair-density values were 192.87 with QR678 Neo versus 135.15 with conventional transplantation: a calculated difference of 57.72 in the report’s unspecified density units. No confidence interval (a range expressing uncertainty around the estimate) was reported; this is not an isolated-peptide effect (Gold 2025, corrected report). No attributable sh-Oligopeptide-4 effect size exists.

Reduced Scalp Flaking ⭕️ Not Central to Hair Regrowth

A randomized study found recombinant thymosin beta-4 improved seborrheic dermatitis (inflammatory scalp disease with flaking), compared with placebo (Yu 2021). This concerns scalp symptoms, not hair regrowth. Applicability is indirect because equivalence of the trial preparation to commercial sh-Oligopeptide-4 is unverified.

Magnitude: Flaking improved versus placebo after four weeks; the retrieved narrative does not report a numerical between-group score difference. Participants had scalp dermatitis, and the formulation contained 0.5 mg/mL recombinant thymosin beta-4 (Yu 2021).

Speculative 🟨

No additional distinct benefit is established: cell-movement and vascular mechanisms are proposed explanations for hair regrowth, already covered above, rather than separate clinical outcomes.

Benefit-Modifying Factors

  • Formulation and route: Human mixture injections and laboratory protein exposure do not establish delivery from a leave-on serum. Concentration, sequence, stability, and access to follicles may change activity; these are plausible modifiers, not validated predictors.
  • Underlying condition: Pattern hair loss, temporary shedding, scalp dermatitis, and scarring loss are different conditions. The dermatitis trial measured scalp symptoms, not restoration of lost follicles (Yu 2021).
  • Baseline markers: No blood or scalp biomarker predicts sh-Oligopeptide-4 response. Testing for other causes of hair loss answers a diagnostic question, not peptide selection.
  • Sex and age: No ingredient-specific evidence establishes different benefits by sex or age, including older adults. Extrapolation from selected adults receiving mixtures remains uncertain.
  • Genetics: No validated genetic variant identifies responders or supports commercial genetic testing for this ingredient.

Potential Risks & Side Effects

Short-term data do not show a clear systemic toxicity signal: a placebo-controlled intravenous recombinant thymosin study reported no serious adverse events or dose-limiting toxicities (effects severe enough to prevent further dosing) (Wang 2021). Its route, preparation, and short observation period do not establish long-term cosmetic scalp safety. Absence of a dedicated drug monograph is not evidence of safety.

High 🟥 🟥 🟥

No risk reaches High: replicated human studies of this isolated ingredient were not found.

Medium 🟥 🟥

No risk reaches Medium: no controlled human study establishes a clinical harm attributable to isolated sh-Oligopeptide-4.

Low 🟥

Injection Pain

A human comparison reported pain during QR678 injections, less often than with platelet-rich plasma (a preparation concentrated from the patient’s blood) (Kapoor 2020). This is indirect procedural evidence from a mixture, not toxicity attributable to sh-Oligopeptide-4 or external application.

Magnitude: Pain was reported by 28% (7/25) receiving QR678 versus 88% (22/25) receiving platelet-rich plasma, a calculated 60 percentage points lower with QR678. The study did not isolate the peptide’s contribution (Kapoor 2020).

Speculative 🟨

Local Irritation or Allergy

Protein ingredients, impurities, or formulation components could provoke scalp irritation or immune reactions. This is a formulation-based inference; no controlled isolated-ingredient study quantifies incidence or identifies susceptible individuals.

Infection After Barrier-Breaking Delivery

Injection or needling can introduce contamination through disrupted skin. This is a procedural inference, not a demonstrated intrinsic peptide toxicity; cosmetic-grade material has no established equivalence to sterile injectable preparations.

Promotion of Existing Malignant Cells

Thymosin beta-4 influenced cell adhesion and invasion in laboratory melanoma (a type of skin cancer) experiments (Makowiecka 2019). This is a mechanistic concern, not evidence that scalp application increases cancer incidence.

Risk-Modifying Factors

  • Skin integrity: Inflamed, broken, or recently needled skin could alter exposure and contamination risk. The magnitude of this change has not been quantified for the ingredient.
  • Prior allergy: Previous reactions to a finished product or its components make another exposure less predictable; this is inferred from immune sensitization, not an ingredient-specific trial.
  • Cancer history: Laboratory findings raise uncertainty about application over known or suspicious skin tumors; no human exposure threshold or quantified cancer risk is available.
  • Sex, pregnancy, and age: Sex-specific safety differences, reproductive effects, and safety in older adults remain uncharacterized. No evidence-based age or sex adjustment is established.
  • Biomarkers and genetics: No validated laboratory marker or genetic variant predicts toxicity. Broad tumor-marker testing cannot establish that prolonged scalp use is safe.

Key Interactions & Contraindications

No retrieved human study establishes interaction effects of isolated sh-Oligopeptide-4 with prescription drugs, nonprescription products, or supplements. Lack of data does not mean combinations are proven compatible; no additive supplement benefit is established.

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Barrier-disrupting procedures: Microneedling or injection may increase exposure and infection risk by bypassing skin protection. Keeping cosmetic application separate from invasive delivery avoids treating an untested cosmetic as an injectable; no validated timing interval exists.
  • Irritating scalp products: Concurrent alcohol-rich minoxidil solutions or exfoliating acids could add local irritation through combined barrier effects. Separating introductions helps identify the responsible product; a spacing interval that prevents this interaction has not been established.

Populations who should avoid sh-Oligopeptide-4:

  • Known allergy to the preparation: Avoidance is inferred from immune re-exposure risk; no ingredient-specific human allergy threshold is established.
  • Application over known or suspected skin malignancy: Avoidance is inferred from experimental effects on cell invasion, not demonstrated human cancer harm (Makowiecka 2019).

No sourced absolute contraindication list was located. Pregnancy, breastfeeding, and serious organ disease remain unstudied rather than proven safe or proven contraindicated.

Risk Mitigation Strategies

Uncited parameters below reflect common practice, not a validated sh-Oligopeptide-4 protocol.

  • Product traceability: Recorded ingredient lists, lot numbers, and storage instructions help investigate irritation, contamination, or batch differences. No purity specification has been clinically validated to eliminate these risks.
  • Route boundaries: Restricting cosmetic preparations to labeled external use avoids injection pain and the infection and uncertain exposure risks of injecting or needling nonsterile material.
  • Local reaction assessment: New persistent redness, swelling, or pain provides a reason to discontinue the product and assess the cause. No numerical peptide-specific stopping threshold exists.
  • Lesion assessment: Examination of a suspicious scalp lesion before local exposure addresses the theoretical malignant-cell concern; routine blood tumor markers do not resolve that concern.
  • Single-change documentation: Introducing one product change at a time helps separate irritation or deterioration caused by the finished product from other treatments.

Therapeutic Protocol

Uncited practical parameters reflect common practice; no standard isolated sh-Oligopeptide-4 hair-regrowth regimen was identified.

  • Established dose: No controlled human hair trial establishes a concentration, amount per scalp area, titration schedule, or maximum dose for the isolated ingredient. A cosmetic ingredient listing does not supply these parameters.
  • Related scalp research: Yu’s dermatitis study used 0.5 mg/mL recombinant thymosin beta-4 alongside shampoo every other day for four weeks. This was a dermatitis protocol, not a validated hair-regrowth dose (Yu 2021).
  • Mixture approach: Kapoor and Shome developed QR678 formulations. Their patented multi-ingredient injection approach cannot be converted into an isolated-peptide dose or reproduced by applying a serum (Kapoor 2020).
  • Timing and frequency: No evidence establishes morning versus evening application or single versus split dosing. Short intravenous half-life does not justify twice-daily scalp application.
  • Half-life: Intravenous recombinant thymosin beta-4 showed a single-dose half-life of approximately 0.5–2.084 hours. Human scalp half-life is unknown (Wang 2021).
  • Personalization: No validated dose adjustment exists for genetic variants, baseline biomarkers, sex, or age. Older adults and people with liver or kidney disease have no established ingredient-specific dosing scheme.
  • Underlying condition: A protocol for scalp inflammation cannot substitute for a protocol for pattern hair loss. Scarred follicles and ongoing inflammatory disease require separate diagnostic interpretation; response to this ingredient has not been established in those settings.

Discontinuation & Cycling

  • Duration: No isolated-ingredient study determines whether treatment should be brief, prolonged, or lifelong. Benefits reported for mixtures do not establish maintenance requirements for a serum.
  • Withdrawal: No defined withdrawal syndrome has been demonstrated. Whether any hair improvement persists after stopping the isolated ingredient is unknown.
  • Tapering: No evidence-based taper exists. There is no established physiological dependence requiring a taper.
  • Cycling: No human evidence supports planned on/off cycles to preserve hair benefit or reduce long-term risk. Claims about “resetting” peptide responsiveness remain untested.

Sourcing and Quality

  • Identity: The exact amino-acid sequence, manufacturing method, and modifications matter. Thymosin beta-4, peptide fragments, and delivery-tagged compounds are not interchangeable solely because a seller uses similar terminology.
  • Finished-product testing: Independent identity and purity testing, microbial limits, stability data, and traceable manufacture are relevant quality checks. A raw-material certificate alone does not show active peptide reaches scalp follicles.
  • Concentration: A percentage of a proprietary peptide blend does not necessarily state the concentration of sh-Oligopeptide-4. Ingredient order is insufficient to reconstruct an experimental dose.
  • Brands and mixtures: QR678 Neo is a studied mixture, not a verified stand-alone source of this ingredient. No brand or compounding pharmacy was identified with independent clinical validation of isolated sh-Oligopeptide-4 for hair regrowth.
  • Storage and delivery: Product-specific storage and expiry information matter because protein instability and poor membrane permeability complicate delivery (Fu 2019). Cosmetic preparations cannot be presumed sterile or suitable for injection.

Practical Considerations

  • Time to effect: No reliable onset estimate exists for isolated sh-Oligopeptide-4. A mixture trial assessed hair outcomes after six months; that timing cannot establish a serum’s expected response (Kapoor 2020).
  • Attribution: Changes in photography, hair length, styling, concurrent therapies, or natural recovery can mimic treatment effects. A mixture’s positive result does not identify which ingredient mattered.
  • Regulatory meaning: The United States Food and Drug Administration treats claims to restore hair growth as drug claims. Cosmetic availability alone does not establish approved hair-regrowth efficacy (FDA cosmetic-or-drug explanation).
  • Cost and access: Isolated ingredient concentrations and clinical protocols are poorly standardized, limiting meaningful price comparisons. Repeated clinic procedures add time and expense without establishing the peptide’s incremental benefit.
  • Commercial incentives: Formulation patent holders have a direct stake in positive mixture results. No specific payer preference or guideline funding bias was documented in the sources retrieved; this review does not infer one from cost alone.

Interaction with Foundational Habits

  • Sleep: No direct beneficial or disruptive interaction has been demonstrated. There is no evidence-based bedtime schedule or reason to infer a sleep effect from tissue-repair biology.
  • Nutrition: No direct dietary interaction or nutrient depletion is established. No food, fasting schedule, or supplement has been shown to potentiate this ingredient; correction of a separate nutritional cause of hair loss is a different intervention.
  • Exercise: No direct interaction with training adaptation has been studied. Sweat, washing, and friction may alter topical contact or irritation, an indirect practical issue rather than evidence of changed hair biology.
  • Stress management: No direct interaction with stress-management practices has been measured. Changing stress and spontaneous shedding can confound before/after observations, so their timing belongs in treatment records rather than being credited to the peptide.

Monitoring Protocol & Defining Success

Baseline assessment documents diagnosis, existing therapies, scalp condition, and standardized photographs. No ingredient-specific blood panel or laboratory safety target is validated. Hair measurements track outcomes without proving treatment efficacy. Consistent scalp sites, lighting, hair length, and counting methods improve comparability.

A pragmatic schedule is baseline, one month for tolerability, and three and six months for photographs and hair measurements, with earlier assessment for new symptoms. These timings reflect common practice, not a tested sh-Oligopeptide-4 protocol. Success means reproducible improvement without persistent scalp symptoms; no minimum meaningful change is established.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hair density at fixed scalp sites No established target; track change from baseline Intended efficacy outcome Same sites and method at baseline, three and six months; no fasting requirement; concurrent treatments confound attribution.
Scalp redness, swelling, and pain No established target; track new or worsening symptoms Safety check affecting continued use Baseline and one month, with symptom-triggered assessment sooner; no validated numerical stopping threshold.
  • Visible coverage: Matched photographs and styling provide a practical outcome alongside counts.
  • Symptoms and acceptability: Persistent itching, discomfort, and treatment burden matter independently of hair counts.
  • Interpretability: A subjective improvement without consistent photographs or measurements remains uncertain, especially when other treatments change.

Emerging Research

  • Registered hair studies: No ongoing ClinicalTrials.gov hair-regrowth trial of isolated sh-Oligopeptide-4 was located. The broader registry search returned cardiovascular studies of related preparations; those cannot answer the hair-efficacy question.
  • Ingredient attribution: A vehicle-controlled study with verified sequence and scalp exposure could establish benefit or show no incremental effect. Corrected mixture research around transplantation provides a rationale for separating these contributions (Gold 2025).
  • Delivery testing: Carrier research addresses poor skin penetration, but better delivery could increase unwanted exposure as well as activity. Human follicular measurements and clinical outcomes would distinguish these possibilities (Fu 2019).
  • Conflicting biology: Favorable rodent findings and inhibitory cultured-human-follicle observations motivate testing across clinically relevant concentrations. The inventor-authored patent is laboratory evidence, not a negative clinical trial (Armbruster–Paus–Langan patent).
  • Long-term safety: Laboratory melanoma findings make prolonged exposure and lesion-specific safety relevant research questions. Either reassuring controlled follow-up or a harm signal would change the current uncertainty (Makowiecka 2019).

Conclusion

sh-Oligopeptide-4 is a cosmetic peptide linked to thymosin beta-4, a protein involved in cell movement and tissue repair. That biology explains interest in hair growth, but it does not establish the effect of a particular scalp product. The human hair evidence concerns mixtures and procedures in which the ingredient’s individual contribution cannot be separated. A related scalp study addresses flaking and inflammation rather than hair regrowth. These distinctions leave the expected hair benefit indirect and uncertain.

The safety picture is similarly incomplete. Short-term research with related preparations offers some reassurance, while neither years of scalp use nor the effects of enhanced delivery are well characterized. Injection pain, local irritation, and contamination during invasive delivery are practical concerns. Laboratory findings involving cancerous cells raise a theoretical issue without demonstrating that cosmetic use causes cancer. Dose, scalp exposure, maintenance schedules, and predictors of response remain undefined.

For adults pursuing durable hair restoration as part of health and longevity goals, willingness to accept expense or demanding routines does not resolve these uncertainties. Formulation developers’ patent interests also matter when interpreting favorable mixture studies. The present evidence supports biological interest and limited, indirect human observations; it does not establish reliable regrowth from isolated sh-Oligopeptide-4 or equivalence among products carrying its name.

Top - Benefits - Risks - Protocol